Spironolactone
Brand names: Carospir, Aldactone, Spironolactone
At a glance
- Medicare prescriptions, 2024
- 7,978,161
- Medicare drug cost
- $70.5M
- Average cost per prescription
- $8.84
- Clinicians who prescribed it
- 175,037
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ALDACTONE is an aldosterone antagonist indicated for: • The treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure. • Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. • Treatment of primary hyperaldosternism for: o Short-term preoperative treatment o Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia
From the FDA-approved prescribing information (label dated November 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 21.6%
- Internal Medicine 19.3%
- Nurse Practitioners 17.8%
- Cardiology 17.5%
- Interventional Cardiology 5.7%
- Physician Assistants 5.6%
- Nephrology (Kidney) 3.0%
- Heart Failure & Transplant Cardiology 2.0%
- Geriatric Medicine 1.2%
- General Practice 1.0%
- Cardiac Electrophysiology 1.0%
- Gastroenterology 0.7%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 43% from 2019 to 2024.
Biggest change by state since 2019
- Connecticut +76%
- District of Columbia +73%
- Alaska +72%
- Utah +70%
- Maryland +60%
- Puerto Rico (smallest change) +19%
- New Mexico (smallest change) +20%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 9 mm | MP 35 |
Pfizer Laboratories Div Pfizer Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow round tablet, 9 mm | SEARLE 1001 ALDACTONE 25 |
| 50 mg | orange oval tablet, 14 mm, scored to split in 2 | SEARLE 1041 ALDACTONE 50 |
| 100 mg | orange round tablet, 11 mm, scored to split in 2 | SEARLE 1031 ALDACTONE 100 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $2,110 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Cmp Pharma, Inc. $2,110
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Aug 2025 · Sun Pharmaceutical Industries Inc · Class II
Presence of foreign substance: identified as aluminum.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.